<DOC>
	<DOC>NCT02756832</DOC>
	<brief_summary>The purpose of this study is to observe clinical response to treatment with alogliptin benzoate (Vipidia) utilization patterns in standard clinical practice.</brief_summary>
	<brief_title>Local, Multicenter, Observational, Non-Interventional Prospective Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2</brief_title>
	<detailed_description>The drug being studied in this study is called alogliptin benzoate. Alogliptin benzoate is being researched to treat people who have diabetes mellitus type 2. This study will look at the glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2. The study will enroll approximately 1403 patients. Alogliptin benzoate will be prescribed by their physician in accordance with the Russian summary of product characteristics (SmPC). This multi-center study will be conducted in the Russian Federation. The overall duration of study for observation will be approximately 6 months. Participants will make multiple visits to the clinic as assigned by each physician according to their routine practice, in every 3 months.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<criteria>1. Male and female participants ≥ 18 years of age; 2. Has a diagnosis of type 2 diabetes mellitus (T2DM) 3. Participants with: newly diagnosed diabetes mellitus (DM) type 2 (drug naïve) or inadequate glycemic control on previously prescribed any oral antidiabetic drug. 4. Vipidia is prescribed according to the approved label for the Russian Federation. 5. The participant's physician decides to prescribe Vipidia: as monotherapy or as a part of combination therapy. 6. The participant (or, when applicable, the participant's legally acceptable representative) signs and dates a written, informed consent form prior to the start of data collection. Participant is capable of understanding the written informed consent, provides signed and written informed consent, and agrees to comply with protocol requirements. In case the participant is blind or unable to read, informed consent will also be witnessed. 1. Contraindications of respective approved Russian summary of product characteristics (SmPC); 2. In the opinion of the physician, the participant has any reasons of medical and nonmedical character, which in the opinion of the physician can prevent participant participation in the study; 3. Had used Dipeptidyl peptidase4 inhibitors (DPPIV inhibitors) or Glucagon like peptide1 agonists (aGLP1) within the 3 months prior to the start of Vipidia treatment. 4. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>